Literature DB >> 16648296

The ternary IGF complex influences postnatal bone acquisition and the skeletal response to intermittent parathyroid hormone.

Shoshana Yakar1, Mary L Bouxsein, Ernesto Canalis, Hui Sun, Vaida Glatt, Caren Gundberg, Pinchas Cohen, David Hwang, Yves Boisclair, Derek Leroith, Clifford J Rosen.   

Abstract

The role of circulating IGF-I in skeletal acquisition and the anabolic response to PTH is not well understood. We generated IGF-I-deficient mice by gene deletions of IGF ternary complex components including: (1) liver-specific deletion of the IGF-I gene (LID), (2) global deletion of the acid-labile (ALS) gene (ALSKO), and (3) both liver IGF-I and ALS inactivated genes (LA). Twelve-week-old male control (CTL), LID, ALSKO, and LA mice were treated with vehicle (VEH) or human PTH(1-34) for 4 weeks. VEH-treated IGF-I-deficient mice (i.e. LID, ALSKO and LA mice) exhibited reduced cortical cross-sectional area (P = 0.001) compared with CTL mice; in contrast, femoral trabecular bone volume fractions (BV/TV) of the IGF-I-deficient mice were consistently greater than CTL (P < 0.01). ALSKO mice exhibited markedly reduced osteoblast number and surface (P < 0.05), as well as mineral apposition rate compared with other IGF-I-deficient and CTL mice. Adherent bone marrow stromal cells, cultured in beta-glycerol phosphate and ascorbic acid, showed no strain differences in secreted IGF-I. In response to PTH, there were both compartment- and strain-specific effects. Cortical bone area was increased by PTH in CTL and ALSKO mice, but not in LID or LA mice. In the trabecular compartment, PTH increased femoral and vertebral BV/TV in LID, but not in ALSKO or LA mice. In conclusion, we demonstrated that the presentation of IGF-I as a circulating complex is essential for skeletal remodeling and the anabolic response to PTH. We postulate that the ternary complex itself, rather than IGF-I alone, influences bone acquisition in a compartment-specific manner (i.e. cortical vs trabecular bone).

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16648296     DOI: 10.1677/joe.1.06657

Source DB:  PubMed          Journal:  J Endocrinol        ISSN: 0022-0795            Impact factor:   4.286


  42 in total

1.  Proteoglycan 4: a dynamic regulator of skeletogenesis and parathyroid hormone skeletal anabolism.

Authors:  Chad M Novince; Megan N Michalski; Amy J Koh; Benjamin P Sinder; Payam Entezami; Matthew R Eber; Glenda J Pettway; Thomas J Rosol; Thomas J Wronski; Ken M Kozloff; Laurie K McCauley
Journal:  J Bone Miner Res       Date:  2012-01       Impact factor: 6.741

2.  Effects of age on parathyroid hormone signaling in human marrow stromal cells.

Authors:  Shuanhu Zhou; Ericka M Bueno; Sung Won Kim; Ilaria Amato; Longxiang Shen; Jochen Hahne; Ilan Bleiberg; Paul Morley; Julie Glowacki
Journal:  Aging Cell       Date:  2011-05-25       Impact factor: 9.304

Review 3.  Building strong bones: molecular regulation of the osteoblast lineage.

Authors:  Fanxin Long
Journal:  Nat Rev Mol Cell Biol       Date:  2011-12-22       Impact factor: 94.444

Review 4.  Catabolic and anabolic actions of parathyroid hormone on the skeleton.

Authors:  B C Silva; A G Costa; N E Cusano; S Kousteni; J P Bilezikian
Journal:  J Endocrinol Invest       Date:  2011-09-23       Impact factor: 4.256

Review 5.  Autocrine and Paracrine Actions of IGF-I Signaling in Skeletal Development.

Authors:  Yongmei Wang; Daniel D Bikle; Wenhan Chang
Journal:  Bone Res       Date:  2013-09-25       Impact factor: 13.567

6.  Misexpression of CCAAT/enhancer binding protein beta causes osteopenia.

Authors:  Stefano Zanotti; Lisa Stadmeyer; Anna Smerdel-Ramoya; Deena Durant; Ernesto Canalis
Journal:  J Endocrinol       Date:  2009-02-13       Impact factor: 4.286

7.  Quantitative ontogeny of murine insulin-like growth factor (IGF)-I, IGF-binding protein-3 and the IGF-related acid-labile subunit.

Authors:  David L Hwang; Phillip D K Lee; Pinchas Cohen
Journal:  Growth Horm IGF Res       Date:  2007-08-23       Impact factor: 2.372

8.  Carbohydrate restriction, prostate cancer growth, and the insulin-like growth factor axis.

Authors:  Stephen J Freedland; John Mavropoulos; Amy Wang; Medha Darshan; Wendy Demark-Wahnefried; William J Aronson; Pinchas Cohen; David Hwang; Bercedis Peterson; Timothy Fields; Salvatore V Pizzo; William B Isaacs
Journal:  Prostate       Date:  2008-01-01       Impact factor: 4.104

9.  The insulin-like growth factor-1 binding protein acid-labile subunit alters mesenchymal stromal cell fate.

Authors:  J Christopher Fritton; Yuki Kawashima; Wilson Mejia; Hayden-Williams Courtland; Sebastien Elis; Hui Sun; Yinjgie Wu; Clifford J Rosen; David Clemmons; Shoshana Yakar
Journal:  J Biol Chem       Date:  2009-12-10       Impact factor: 5.157

10.  Serum complexes of insulin-like growth factor-1 modulate skeletal integrity and carbohydrate metabolism.

Authors:  Shoshana Yakar; Clifford J Rosen; Mary L Bouxsein; Hui Sun; Wilson Mejia; Yuki Kawashima; Yingjie Wu; Kelly Emerton; Valerie Williams; Karl Jepsen; Mitchell B Schaffler; Robert J Majeska; Oksana Gavrilova; Mariana Gutierrez; David Hwang; Patricia Pennisi; Jan Frystyk; Yves Boisclair; John Pintar; Héctor Jasper; Horacio Domene; Pinchas Cohen; David Clemmons; Derek LeRoith
Journal:  FASEB J       Date:  2008-10-24       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.